FDA Early Alert

Baxter Volara System Patient Circuits

FDA Issues Early Alert for Baxter Volara System Patient Circuits Following Therapy Leakage Concerns

The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potentially high-risk issue affecting certain Baxter Volara System patient circuits used in respiratory therapy.

According to Baxter, affected single-patient-use circuits may experience air and medication leakage from the nebulizer cup during therapy, potentially reducing the effectiveness of prescribed treatment and increasing the risk of respiratory complications.

The FDA is currently reviewing the issue and will continue providing updates as additional information becomes available.

Affected Devices

The alert applies to certain Volara System patient circuits used with the Baxter Volara respiratory therapy platform, including:

  • Volara Patient Circuit Kit HC
  • Volara Patient Circuit 5 Kit
  • Volara Patient Circuit Kit AC
  • Volara Patient Circuit 5 Kit AC

Healthcare facilities and home-care providers should review Baxter’s Urgent Medical Device Correction notice to identify affected inventory.

Potential Patient Risks

Baxter reported that leakage may occur if the nebulizer cup is damaged or not fully engaged and locked after medication is added.

When leakage occurs, patients may receive less medication than intended and experience reduced therapeutic benefit.

Potential adverse consequences include:

  • Ineffective nebulization
  • Reduced medication delivery to the lungs
  • Increased airway inflammation
  • Mucus retention
  • Mucus plugging
  • Respiratory infection
  • Prolonged coughing
  • Worsening shortness of breath
  • Reduced oxygenation

In addition, air leaks within the breathing circuit may result in lower-than-prescribed tidal volumes, potentially leading to hypoxia, hypoventilation, and respiratory compromise. The risk may be particularly significant for pediatric patients receiving therapy in the home-care setting.

As of May 21, 2026, Baxter reported one serious injury associated with the issue. No deaths have been reported.

Recommended Actions

Baxter recommends that healthcare providers, caregivers, and patients:

  • Carefully inspect the nebulizer cup before each use.
  • Ensure the nebulizer cup is filled and securely locked during assembly.
  • Discontinue use and replace the patient circuit if leakage is observed.
  • Contact a healthcare provider if leakage persists or there is uncertainty about continuing therapy.
  • Distribute the correction notice to all users and affected facilities.

Replacement patient circuits remain available through normal distribution channels.

Regulatory Perspective

The FDA’s Early Alert program is designed to rapidly communicate potentially serious device issues before the agency completes a full evaluation.

This alert highlights the importance of component-level verification and user assembly processes in respiratory therapy systems. While the reported issue appears linked to nebulizer cup engagement, the resulting therapy interruption can affect both mechanical and pharmacologic treatment outcomes.

For respiratory support devices, even seemingly minor assembly issues can result in reduced treatment effectiveness and patient harm, particularly among vulnerable patient populations.

MDP Takeaway

Healthcare organizations using Baxter Volara Systems should immediately review Baxter’s correction notice, educate respiratory therapy and clinical staff regarding proper nebulizer cup assembly, and reinforce pre-use inspection procedures.

Home-care providers should ensure patients and caregivers understand how to identify leakage and when to discontinue therapy.

Given the potential for hypoxia, hypoventilation, and reduced medication delivery, organizations should treat this issue as a high-priority respiratory therapy safety concern until corrective actions are fully implemented.

Links

Read the FDA’s announcement here.

Medical Device Recalls

Intersurgical 22mm Smoothbore Breathing Tubes and Systems

FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...

FDA Early Alert: Teleflex/Arrow Guidewire

Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...

FDA Investigates Cancer Risk with Zolgensma Gene Therapy

Postmarketing reports identify cases of tumor formation linked to gene therapy vector integration, prompting FDA to evaluate potential regulatory action.The U.S. Food and Drug Administration (FDA) is investigating a serious potential cancer risk associated with...

Eugia Vancomycin Recall: Glass Particle Contamination

FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...

FDA Requires New GLP-1 Drug Warning for Vision Loss Risk

Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...

Class 1 Recall for HemosIL AcuStar HIT Antibody Test

HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...